Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769322 · ClinicalTrials.gov registry record
Real World Data Analysis: Impact of High-Frequency REN Treatments As Migraine Preventive Therapy in Adolescence
A clinical trial, sponsored by Theranica.
- Completed
- Registry status
- 83
- Enrollment target
NCT05769322 is a clinical trial that has completed, run by Theranica. The registered enrollment target is 83 participants.
The verdict
NCT05769322 has completed, sponsored by Theranica.
- COMPLETED
- Registry status
- 83 participants
- Enrollment target
Study Summary
This is a post-marketing study investigating the safety and efficacy of the REN device (Nerivio by Theranica, ISRAEL) in adolescents with migraine. The data analysis will test the ability of Frequent use of REN for the acute treatment of migraine to reduce the number of monthly migraine days in subsequent months, suggesting potential preventive benefits.
Interventions
- DEVICE Nerivio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2023-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05769322
The ClinicalTrials.gov registry entry for NCT05769322 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theranica, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nerivio is the first listed.
NCT05769322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05769322 about?
NCT05769322 is a clinical study titled "Real World Data Analysis: Impact of High-Frequency REN Treatments As Migraine Preventive Therapy in Adolescence". This is a post-marketing study investigating the safety and efficacy of the REN device (Nerivio by Theranica, ISRAEL) in adolescents with migraine. The data analysis will test the ability of Frequent use of REN for the acute treatment of migraine to reduce the number of monthly migraine days in subs...
What is the current status of trial NCT05769322?
This trial is currently completed. The enrollment target is 83 participants. The study started on 2023-04-01. Estimated completion is 2023-05-01.
What interventions are being tested in trial NCT05769322?
The interventions under investigation include: Nerivio (DEVICE).
Who is sponsoring clinical trial NCT05769322?
This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.